Target Indications

NIU

Eyevensys is currently targeting Uveitis, as its lead programme.

Uveitis is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. The uvea consists of the middle layer of pigmented vascular structures of the eye and includes the iris, ciliary body, and choroid.

Uveitis is classified anatomically into anterior, intermediate, posterior, and panuveitic forms—based on the part of the eye primarily affected.

  • Anterior uveitis is the inflammation of the anterior chamber and iris. Anywhere from two-thirds to 90% of uveitis cases are anterior in location. This condition can occur as a single episode and subside with proper treatment or may take on a recurrent or chronic nature.
  • Intermediate uveitis is the inflammation of cells in the vitreous cavity.
  • Posterior uveitis or chorioretinitis is the inflammation of the retina and choroid.
  • Pan-uveitis is the inflammation of all layers of the uvea.

Uveitis often has an autoimmune component. HLA-B27 positive anterior uveitis is the most common identifiable cause of anterior uveitis. Among non-infectious posterior uveitis, the most frequent aetiology are: Behçet disease, Vogt-Koyanagi-Harada disease, Birdshot retinopathy, pars planitis, idiopathic retinal vasculitis and multifocal retinochorioditis.

The lead indication pursued by Eyevensys is non-infectious intermediate and posterior uveitis (NIU). Representing over 10% of uveitis cases, it is the 4th cause of blindness, and can considered a rare disease afflicting 3,3 to 3,8 in 10 000 people, i.e. 250,000 patients in North America and Europe. The indication has been granted Orphan disease designation in EU and in the US. Market is estimated over 250 M€, growing at a rate of 6,5% per year.